Current Application of Neurofilaments in Amyotrophic Lateral Sclerosis and Future Perspectives

Overview

Journal Neural Regen Res

Date 2021 Mar 1

PMID 33642372

Citations 16

Authors

Yuri Matteo Falzone

Tommaso Russo

Teuta Domi

Laura Pozzi

Angelo Quattrini

Massimo Filippi

Nilo Riva

Affiliations

Soon will be listed here.

Abstract

Motor neuron disease includes a heterogeneous group of relentless progressive neurological disorders defined and characterized by the degeneration of motor neurons. Amyotrophic lateral sclerosis is the most common and aggressive form of motor neuron disease with no effective treatment so far. Unfortunately, diagnostic and prognostic biomarkers are lacking in clinical practice. Neurofilaments are fundamental structural components of the axons and neurofilament light chain and phosphorylated neurofilament heavy chain can be measured in both cerebrospinal fluid and serum. Neurofilament light chain and phosphorylated neurofilament heavy chain levels are elevated in amyotrophic lateral sclerosis, reflecting the extensive damage of motor neurons and axons. Hence, neurofilaments are now increasingly recognized as the most promising candidate biomarker in amyotrophic lateral sclerosis. The potential usefulness of neurofilaments regards various aspects, including diagnosis, prognosis, patient stratification in clinical trials and evaluation of treatment response. In this review paper, we review the body of literature about neurofilaments measurement in amyotrophic lateral sclerosis. We also discuss the open issues concerning the use of neurofilaments clinical practice, as no overall guideline exists to date; finally, we address the most recent evidence and future perspectives.

Citing Articles

Development of a Novel Microphysiological System for Peripheral Neurotoxicity Prediction Using Human iPSC-Derived Neurons with Morphological Deep Learning.

Han X, Matsuda N, Yamanaka M, Suzuki I Toxics. 2024; 12(11).

PMID: 39590989 PMC: 11598741. DOI: 10.3390/toxics12110809.

Neurofilament light chain in serum of cancer patients with acute neurological complications.

Gottiparthy A, Lam K, Kundu S, Yang Z, Tremont-Lukats I, Tummala S CNS Oncol. 2024; 13(1):2386233.

PMID: 39136375 PMC: 11323868. DOI: 10.1080/20450907.2024.2386233.

Neurofilament Biophysics: From Structure to Biomechanics.

Ding E, Kumar S Mol Biol Cell. 2024; 35(5):re1.

PMID: 38598299 PMC: 11151108. DOI: 10.1091/mbc.E23-11-0438.

Chitinases as a potential diagnostic and prognostic biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Xu A, Luo Y, Tang Y, Yang F, Gao X, Qiao G Neurol Sci. 2024; 45(6):2489-2503.

PMID: 38194198 PMC: 11081993. DOI: 10.1007/s10072-024-07301-5.

Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.

De Marchi F, Franjkic T, Schito P, Russo T, Nimac J, Chami A Biomedicines. 2023; 11(6).

PMID: 37371694 PMC: 10295684. DOI: 10.3390/biomedicines11061599.

References

Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M . Delayed diagnosis in ALS: the problem continues. J Neurol Sci. 2014; 343(1-2):173-5. DOI: 10.1016/j.jns.2014.06.003. View

Tortelli R, Ruggieri M, Cortese R, DErrico E, Capozzo R, Leo A . Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012; 19(12):1561-7. DOI: 10.1111/j.1468-1331.2012.03777.x. View

Lanznaster D, Hergesheimer R, Bakkouche S, Beltran S, Vourch P, Andres C . Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2020; 21(8). PMC: 7216266. DOI: 10.3390/ijms21082911. View

Schreiber S, Spotorno N, Schreiber F, Acosta-Cabronero J, Kaufmann J, Machts J . Significance of CSF NfL and tau in ALS. J Neurol. 2018; 265(11):2633-2645. DOI: 10.1007/s00415-018-9043-0. View

Steinacker P, Huss A, Mayer B, Grehl T, Grosskreutz J, Borck G . Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. 2016; 18(1-2):112-119. DOI: 10.1080/21678421.2016.1241279. View

Sandelius A, Zetterberg H, Blennow K, Adiutori R, Malaspina A, Laura M . Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018; 90(6):e518-e524. PMC: 5818017. DOI: 10.1212/WNL.0000000000004932. View

Maglemose R, Hedegaard A, Lehnhoff J, Dimintiyanova K, Moldovan M, Grondahl L . Potassium channel abnormalities are consistent with early axon degeneration of motor axons in the G127X SOD1 mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2017; 292:154-167. DOI: 10.1016/j.expneurol.2017.03.008. View

Altmann P, De Simoni D, Kaider A, Ludwig B, Rath J, Leutmezer F . Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. J Neuroinflammation. 2020; 17(1):86. PMC: 7079539. DOI: 10.1186/s12974-020-01737-0. View

Didonna A, Opal P . The role of neurofilament aggregation in neurodegeneration: lessons from rare inherited neurological disorders. Mol Neurodegener. 2019; 14(1):19. PMC: 6524292. DOI: 10.1186/s13024-019-0318-4. View

10.

Agosta F, Ferraro P, Riva N, Spinelli E, Domi T, Carrera P . Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging. 2017; 57:206-219. DOI: 10.1016/j.neurobiolaging.2017.05.024. View

11.

Verde F, Steinacker P, Weishaupt J, Kassubek J, Oeckl P, Halbgebauer S . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018; 90(2):157-164. DOI: 10.1136/jnnp-2018-318704. View

12.

Kuhle J, Plavina T, Barro C, Disanto G, Sangurdekar D, Singh C . Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Scler. 2019; 26(13):1691-1699. PMC: 7604552. DOI: 10.1177/1352458519885613. View

13.

Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S . Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol. 2017; 74(5):525-532. PMC: 5822207. DOI: 10.1001/jamaneurol.2016.5398. View

14.

Majumder V, Gregory J, Barria M, Green A, Pal S . TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018; 18(1):90. PMC: 6027783. DOI: 10.1186/s12883-018-1091-7. View

15.

Weydt P, Oeckl P, Huss A, Muller K, Volk A, Kuhle J . Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2015; 79(1):152-8. DOI: 10.1002/ana.24552. View

16.

Wilke C, Pujol-Calderon F, Barro C, Stransky E, Blennow K, Michalak Z . Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clin Chem Lab Med. 2019; 57(10):1556-1564. DOI: 10.1515/cclm-2019-0015. View

17.

Darras B, Crawford T, Finkel R, Mercuri E, De Vivo D, Oskoui M . Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019; 6(5):932-944. PMC: 6530526. DOI: 10.1002/acn3.779. View

18.

McCauley M, ORourke J, Yanez A, Markman J, Ho R, Wang X . C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020; 585(7823):96-101. PMC: 7484469. DOI: 10.1038/s41586-020-2625-x. View

19.

Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R . Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020; 95(1):e59-e69. PMC: 7371380. DOI: 10.1212/WNL.0000000000009559. View

20.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016; 54(10):1655-61. DOI: 10.1515/cclm-2015-1195. View